PE20190503A1 - Moduladores del receptor nmda espiro-lactam y uso de los mismos - Google Patents

Moduladores del receptor nmda espiro-lactam y uso de los mismos

Info

Publication number
PE20190503A1
PE20190503A1 PE2019000296A PE2019000296A PE20190503A1 PE 20190503 A1 PE20190503 A1 PE 20190503A1 PE 2019000296 A PE2019000296 A PE 2019000296A PE 2019000296 A PE2019000296 A PE 2019000296A PE 20190503 A1 PE20190503 A1 PE 20190503A1
Authority
PE
Peru
Prior art keywords
halogen
independently selected
nmda
alkyl
espiro
Prior art date
Application number
PE2019000296A
Other languages
English (en)
Inventor
M Amin Khan
Original Assignee
Aptinyx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aptinyx Inc filed Critical Aptinyx Inc
Publication of PE20190503A1 publication Critical patent/PE20190503A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4747—Quinolines; Isoquinolines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Abstract

Se refiere a un compuesto representado por la formula expuesta, o una sal farmaceuticamente aceptable y/o un estereoisomero del mismo, caracterizado porque: X y Y son NR1 o CR2R2 (uno de estos es NR1); R1 se selecciona de H, alquiloC1-C6, entre otros; q es 0 o 1; r es 1 o 2; R2 se selecciona de forma independiente de H, halogeno, entre otros; R3 se selecciona de H, fenilo, entre otros; R5 se selecciona de forma independiente de H, alquiloC1-C6, entre otros; R6 es 1 o 2 sustituyentes por cada carbono de anillo disponible (se selecciona de halogeno, alquiloC1-C6, entre otros); R7 se selecciona de forma independiente de H, halogeno, entre otros; y R9 se selecciona de forma independiente de H, halogeno, entre otros; y a una formulacion o composicion farmaceutica que comprende al compuesto de la invencion (puede ser su mezcla racemica) junto a un excipiente farmaceuticamente aceptable (segun su via de administracion. Tambien se refiere a metodos de preparacion y de tratamiento (para esto tambien se pueden emplear terapias de combinacion con uno o mas de otros agentes activos). La presente invencion es util para el tratamiento de afecciones tales como depresion y trastornos relacionados mediante la modulacion de la actividad del receptor de N-metil-d-aspartato (NMDA).
PE2019000296A 2016-08-01 2017-08-01 Moduladores del receptor nmda espiro-lactam y uso de los mismos PE20190503A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662369453P 2016-08-01 2016-08-01

Publications (1)

Publication Number Publication Date
PE20190503A1 true PE20190503A1 (es) 2019-04-10

Family

ID=59582038

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019000296A PE20190503A1 (es) 2016-08-01 2017-08-01 Moduladores del receptor nmda espiro-lactam y uso de los mismos

Country Status (17)

Country Link
US (3) US11299495B2 (es)
EP (1) EP3490992B1 (es)
JP (2) JP2019527233A (es)
KR (1) KR102465758B1 (es)
CN (1) CN109937204B (es)
AU (2) AU2017306152A1 (es)
BR (1) BR112019001768A2 (es)
CA (1) CA3031537A1 (es)
CL (1) CL2019000248A1 (es)
CO (1) CO2019000945A2 (es)
EA (1) EA201990424A1 (es)
IL (1) IL264514B (es)
MX (1) MX2019001319A (es)
PE (1) PE20190503A1 (es)
PH (1) PH12019500202A1 (es)
SG (2) SG10202101055VA (es)
WO (1) WO2018026779A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101769999B1 (ko) 2008-09-18 2017-08-21 노오쓰웨스턴 유니버시티 Ｎｍｄａ 수용체 조절제 및 그의 용도
LT2951183T (lt) 2013-01-29 2019-05-27 Aptinyx Inc. Spiro-laktamo nmda receptorių moduliatoriai ir jų panaudojimas
CA3031539C (en) 2016-08-01 2023-11-28 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
CA3031537A1 (en) 2016-08-01 2018-02-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
KR102462288B1 (ko) 2016-08-01 2022-11-01 앱티닉스 인크. 스피로-락탐 및 비스-스피로-락탐 nmda 수용체 조정제 및 그의 용도
CN109843889B (zh) 2016-08-01 2022-03-15 阿普廷伊克斯股份有限公司 螺-内酰胺nmda调节剂和使用其的方法
KR102503590B1 (ko) 2016-08-01 2023-02-24 앱티닉스 인크. 스피로-락탐 nmda 수용체 조정제 및 그의 용도
CN112204031A (zh) * 2018-01-31 2021-01-08 阿普廷伊克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
CN109608460A (zh) * 2018-12-17 2019-04-12 上海合全药业股份有限公司 一种1,10-二氧亚基-2,7-二氮杂螺[4.5]癸烷-7-甲酸叔丁酯的合成方法
WO2021228123A1 (zh) * 2020-05-12 2021-11-18 北京广为医药科技有限公司 调节nmda受体活性的化合物、其药物组合物及用途
CN114591326B (zh) * 2022-02-28 2024-02-27 上海筛杰生物医药有限公司 Cct-251921的中间体及其制备方法

Family Cites Families (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0180398A1 (en) 1984-10-26 1986-05-07 The Regents Of The University Of California Synthesis of beta-lactam
CA1305177C (en) 1987-06-30 1992-07-14 Yasufumi Ohfune Carboxycyclopropylglycine and process for producing the same
US4904681A (en) 1987-12-01 1990-02-27 G. D. Searle & Co. D-cycloserine and its prodrugs as cognitive enhancers
EP0360390A1 (en) 1988-07-25 1990-03-28 Glaxo Group Limited Spirolactam derivatives
US5061721A (en) 1989-03-15 1991-10-29 G. D. Searle & Co. Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
US5086072A (en) 1990-06-18 1992-02-04 The United States Of America As Represented By The Department Of Health And Human Services Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex
WO1992007561A1 (fr) 1990-10-30 1992-05-14 Ss Pharmaceutical Co., Ltd. Preparation d'un gel anti-inflammatoire et analgesique
US5168103A (en) 1991-01-22 1992-12-01 American Home Products Corporation [[2-(amino-3,4-dioxo-1-cyclobuten-1-yl) amino]alkyl]-acid derivatives
FR2692268B1 (fr) 1992-06-15 1994-08-19 Rhone Poulenc Rorer Sa Nouveaux polypeptides ayant une activité de récepteur NMDA, acides nucléiques codant pour ces polypeptides et utilisations.
SE9301667D0 (sv) 1993-05-14 1993-05-14 Kabi Pharmacia Ab New use
US5523323A (en) 1993-09-14 1996-06-04 Maccecchini; Maria-Luisa Use of partial agonists of the NMDA receptor to reduce opiate induced tolerance and dependence
US5605911A (en) 1995-01-31 1997-02-25 Washington University Use of alpha-2 adrenergic drugs to prevent adverse effects of NMDA receptor hypofunction (NRH)
US6335358B1 (en) 1995-04-12 2002-01-01 President And Fellows Of Harvard College Lactacystin analogs
US5741778A (en) 1996-03-19 1998-04-21 Amgen Inc. Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein product
US5763393A (en) 1996-05-17 1998-06-09 Neurotherapeutics L.P. Neuroactive peptides
ATE283278T1 (de) 1996-06-07 2004-12-15 Astrazeneca Ab Peptid derivate
US5959075A (en) 1996-08-02 1999-09-28 Zymogenetics, Inc. Testis-specific insulin homolog polypeptides
US5902815A (en) 1996-09-03 1999-05-11 Washington University Use of 5HT-2A serotonin agonists to prevent adverse effects of NMDA receptor hypofunction
JP3955345B2 (ja) 1996-09-27 2007-08-08 サントリー株式会社 新規アミノ酸ダイジハーベイン
WO1999024584A1 (en) 1997-11-12 1999-05-20 Neurotherapeutics Methods for the detection and treatment of disease using a glycosyltransferase
US5952389A (en) 1998-01-13 1999-09-14 Synchroneuron Methods of treating tardive dyskinesia and other movement disorders
US6007841A (en) 1998-03-13 1999-12-28 Algos Pharmaceutical Corporation Analgesic composition and method for treating pain
US6274314B1 (en) 1998-04-02 2001-08-14 Nyxis Neurotherapies, Inc. Diagnostic assay for the modified nucleosides pseudouridine, 7-methyladenosine, or 1-methyladenosine
US6197820B1 (en) 1998-04-06 2001-03-06 Uab Research Foundation Use of phenylglycine derivatives to decrease neuronal death caused by brain tumors and brain lesions
US6025471A (en) 1998-06-03 2000-02-15 Deghenghi; Romano Diazaspiro, azepino and azabicyclo therapeutic peptides
WO2000027790A1 (en) 1998-11-11 2000-05-18 Smithkline Beecham P.L.C. Mutilin compounds
WO2000028090A2 (en) 1998-11-12 2000-05-18 Nyxis, Inc. Diagnostic assay for cancer
US20030064921A1 (en) 1999-10-27 2003-04-03 The Regents Of The University Of California Methods and compounds for modulating melanocortin receptor ligand binding and activity
WO2001036685A2 (en) 1999-11-17 2001-05-25 Nyxis Neurotherapies, Inc. Differential gene expression in cancer
JP2003521247A (ja) 2000-02-01 2003-07-15 エージーワイ セラピューティクス インコーポレーテッド Ｎｍｄａ受容体のプロテインチロシンホスファターゼとの相互作用
JP2001261679A (ja) 2000-03-21 2001-09-26 Mitsui Chemicals Inc ピロリジノン誘導体及びそれらの製造方法並びに該化合物を含有する医薬
WO2001096606A2 (en) 2000-06-14 2001-12-20 Nyxis Neurotherapies, Inc. Identification of genes and compounds for treatment of cancer
EP1296999A2 (en) 2000-06-22 2003-04-02 NYXIS NeuroTherapies, Inc. Neuroactive peptides for treatment of hypoxia and related conditions
GB0018272D0 (en) 2000-07-25 2000-09-13 Vernalis Research Limited Chemical compounds IV
EP1186303A3 (en) 2000-09-06 2003-12-10 Pfizer Products Inc. Pharmaceutical combinations, for the treatment of stroke and traumatic brain injury, containing a neutrophil inhibiting factor and an selective NMDA-NR2B receptor antagonist
IL145209A0 (en) 2000-09-06 2002-06-30 Pfizer Prod Inc Pharmaceutical combinations for the treatment of stroke and traumatic brain injury
UA73619C2 (en) 2000-12-13 2005-08-15 Pfizer Prod Inc Stable pharmaceutical compositions of nmda receptor agonist (variants) and method of treatment
AU2002236608A1 (en) 2000-12-14 2002-06-24 Nyxis Neurotherapies, Inc. High throughput assay to detect inhibitors of the map kinase pathway
AU2002248553A1 (en) 2001-03-07 2002-09-24 Cognetix, Inc Linear y-carboxyglutamate rich conotoxins
AU2002255705A1 (en) 2001-03-12 2002-09-24 Nyxis Neurotherapies, Inc Neuroactive peptides for prevention and/or treatment of hypoxia and neuropathic pain
US20030022253A1 (en) 2001-07-25 2003-01-30 Nyxis Neurotherapies, Inc. Method for identifying, isolating and producing neuroactive binding agents and binding agents derived thereby
ES2355157T3 (es) 2002-07-05 2011-03-23 Targacept, Inc. Compuestos diazaspirocíclico n-arilo y métodos de preparación y uso de las mismas.
US7273889B2 (en) 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
WO2004094371A2 (en) 2003-04-17 2004-11-04 Merck & Co., Inc. Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity
EP1776362A1 (en) 2003-07-18 2007-04-25 Virochem Pharma Inc. Spiro compounds and methods for the modulation of chemokine receptor activity
WO2005014797A2 (en) 2003-08-08 2005-02-17 The Burnham Institute P16 mediated regulation of nmda receptors
WO2005020973A2 (en) 2003-08-29 2005-03-10 The University Of Houston System Compositions having antimycrobial activity including a hydroxamate or a hydroxamate and a hydroxylamine
GB0323204D0 (en) 2003-10-03 2003-11-05 Novartis Ag Organic compounds
US20050096311A1 (en) 2003-10-30 2005-05-05 Cns Response Compositions and methods for treatment of nervous system disorders
US20070275990A1 (en) 2003-11-13 2007-11-29 Ono Pharmaceutical Co., Ltd. Heterocyclic Spiro Compound
ES2359707T3 (es) * 2004-01-08 2011-05-26 F. Hoffmann-La Roche Ag Derivados de diaza-espiropiperidina.
CA2575461A1 (en) * 2004-08-20 2006-03-02 Targacept, Inc. The use of n-aryl diazaspiracyclic compounds in the treatment of addiction
WO2006034196A1 (en) 2004-09-17 2006-03-30 Lifelike Biomatic Inc. Compositions for enhancing memory and methods therefor
CN101090902B (zh) * 2004-10-13 2013-05-29 默沙东公司 Cgrp受体拮抗剂
CA2602950C (en) 2005-03-24 2012-10-30 Emory University Methods for the treatment of central nervous system injury via a tapered administration of progesterone
CA2620361C (en) 2005-08-26 2014-10-14 Wisconsin Alumni Research Foundation Poly-beta-peptides from functionalized beta-lactam monomers and antibacterial compositions containing same
AR059224A1 (es) 2006-01-31 2008-03-19 Jerini Ag Compuestos para la inhibicion de integrinas y uso de estas
WO2007103719A2 (en) 2006-03-03 2007-09-13 Incyte Corporation MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
MX2009002921A (es) 2006-09-15 2009-04-01 Schering Corp Derivados de azetidinona para el tratamiento de trastornos del metabolismo lipidico.
JP2008188285A (ja) 2007-02-06 2008-08-21 Bridgestone Corp バックパッド及び車両用シート
CA2682195A1 (en) 2007-03-20 2008-09-25 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
CN101066945B (zh) 2007-05-25 2010-05-19 中国科学院上海有机化学研究所 一种合成3-位取代内酰胺类化合物的方法
CN101125817B (zh) 2007-08-03 2011-09-14 中国科学院上海有机化学研究所 一种合成高对映选择性醛基取代小环胺类化合物和光学活性3-位取代内酰胺类化合物的方法
US20090054392A1 (en) 2007-08-20 2009-02-26 Wyeth Naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system
WO2009039390A2 (en) 2007-09-20 2009-03-26 Naurex Inc. The development of glycobiology-based therapeutics for the treatment of brain tumors
EP2257644B1 (en) 2008-02-20 2015-06-24 The Children's Hospital Of Philadelphia Genetic alterations associated with autism and the autistic phenotype and methods of use thereof for the diagnosis of autism
US20110105480A1 (en) 2008-06-24 2011-05-05 Keith Freehauf Pharmaceutical transdermal compositions and method for treating inflammation in cattle
RU2011102523A (ru) 2008-06-27 2012-08-10 Ньюросерч А/С (DK) Новые производные тетраметил-замещенного пиперидина и их применение в качестве ингибиторов обратного захвата моноаминовых нейромедиаторов
ES2461841T3 (es) 2008-08-07 2014-05-21 F. Hoffmann-La Roche Ag Proceso para la preparación de un macrociclo
GB0814991D0 (en) 2008-08-15 2008-09-24 Glaxo Group Ltd Compounds
KR101769999B1 (ko) 2008-09-18 2017-08-21 노오쓰웨스턴 유니버시티 Ｎｍｄａ 수용체 조절제 및 그의 용도
WO2010065709A2 (en) 2008-12-03 2010-06-10 Amin Khan Hydroxamic acid derivatives, preparation and therapeutic uses thereof
DE102009001460B4 (de) 2009-03-11 2010-12-02 Zf Friedrichshafen Ag Ölbehälter
US8329904B2 (en) * 2009-05-12 2012-12-11 Hoffmann-La Roche Inc. Azacyclic derivatives
WO2011003064A2 (en) 2009-07-02 2011-01-06 Naurex, Inc. Methods of treating neuropathic pain
RS53513B1 (en) 2009-10-05 2015-02-27 Northwestern University GLYX-13 FOR USE IN THE REFRACTOR DEPRESSION TREATMENT PROCEDURE
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
US8871208B2 (en) * 2009-12-04 2014-10-28 Abbvie Inc. 11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors and uses thereof
ES2459496T3 (es) 2009-12-21 2014-05-09 Novartis Ag Diaza-espiro[5.5]undecanos como antagonistas del receptor de orexina
CN102933226A (zh) 2010-02-11 2013-02-13 西北大学 二级结构稳定化的nmda受体调节剂及其用途
KR101692275B1 (ko) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
UY33227A (es) * 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
US8097634B2 (en) 2010-04-15 2012-01-17 Hoffmann-La Roche Inc. Azacyclic derivatives
GB201007789D0 (en) * 2010-05-10 2010-06-23 Glaxo Group Ltd Novel Compound
CN102267995A (zh) * 2010-06-04 2011-12-07 艾琪康医药科技（上海）有限公司 一种制备二氮杂螺环化合物的方法
TW201245116A (en) 2010-08-12 2012-11-16 Tetraphase Pharmaceuticals Inc Tetracycline analogs
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
KR20140014184A (ko) 2011-02-25 2014-02-05 아이알엠 엘엘씨 Trk 억제제로서의 화합물 및 조성물
AP3339A (en) * 2011-03-14 2015-07-31 Boehringer Ingelheim Int Benzodioxane inhibitors of leukotriene production
KR20140043078A (ko) 2011-04-27 2014-04-08 노오쓰웨스턴 유니버시티 알츠하이머병, 헌팅톤병, 자폐증 또는 기타 장애의 치료 방법
US9293690B2 (en) 2011-06-27 2016-03-22 Koninklijke Philips N.V. Ultrasound transducer assembly and method of manufacturing the same
CA2842647A1 (en) 2011-07-18 2013-01-24 The Governors Of The University Of Alberta Catalysts and processes for the hydrogenation of amides
CN104109161B (zh) 2011-07-27 2016-08-17 阿斯利康(瑞典)有限公司 2-(2,4,5-取代苯胺)嘧啶衍生物作为egfr调谐子用于治疗癌症
CN103172641B (zh) 2011-12-20 2014-06-11 钱卫 杂环胺基烷氧基取代的喹唑啉衍生物及其用途
AR092031A1 (es) 2012-07-26 2015-03-18 Merck Sharp & Dohme Inhibidores del canal de potasio medular externo renal
CN102936216B (zh) 2012-12-05 2015-03-04 南京药石药物研发有限公司 7,9-二氧代-2,6-氮杂-螺[3.5]壬-2-甲酸叔丁酯及其中间体的制备方法
US9738650B2 (en) 2013-01-29 2017-08-22 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
LT2951183T (lt) 2013-01-29 2019-05-27 Aptinyx Inc. Spiro-laktamo nmda receptorių moduliatoriai ir jų panaudojimas
PE20151437A1 (es) * 2013-01-29 2015-10-10 Naurex Inc Moduladores de receptores nmda de espiro-lactama y sus usos
EP2951182B1 (en) 2013-01-29 2020-03-18 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
EP2951185B1 (en) 2013-01-29 2016-12-21 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
CN103171641B (zh) 2013-03-19 2015-07-15 浙江大学 具备轮动功能的弹跳机器人
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
GB2528480A (en) 2014-07-23 2016-01-27 Givaudan Sa Improvements in or relating to organic compounds
GB201416346D0 (en) * 2014-09-16 2014-10-29 Shire Internat Gmbh Spirocyclic derivatives
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
MX2018014202A (es) 2016-05-19 2019-06-20 Aptinyx Inc Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos.
KR102503590B1 (ko) 2016-08-01 2023-02-24 앱티닉스 인크. 스피로-락탐 nmda 수용체 조정제 및 그의 용도
KR102462288B1 (ko) 2016-08-01 2022-11-01 앱티닉스 인크. 스피로-락탐 및 비스-스피로-락탐 nmda 수용체 조정제 및 그의 용도
CN109843889B (zh) 2016-08-01 2022-03-15 阿普廷伊克斯股份有限公司 螺-内酰胺nmda调节剂和使用其的方法
CA3031537A1 (en) 2016-08-01 2018-02-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
CA3031539C (en) 2016-08-01 2023-11-28 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
MX2020008106A (es) 2018-01-31 2020-09-25 Aptinyx Inc Moduladores del receptor nmda espiro-lactama y usos de los mismos.
CN112204031A (zh) 2018-01-31 2021-01-08 阿普廷伊克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
US20210308101A1 (en) 2019-11-11 2021-10-07 Aptinyx Inc. Methods of treating fibromyalgia
US20210139489A1 (en) 2019-11-11 2021-05-13 Aptinyx Inc. Methods of treating painful diabetic peripheral neuropathy
AU2020398840A1 (en) 2019-12-04 2022-05-26 Aptinyx Inc. Methods of treating cognitive impairment associated with neurodegenerative disease

Also Published As

Publication number Publication date
AU2017306152A1 (en) 2019-01-31
CN109937204A (zh) 2019-06-25
EA201990424A1 (ru) 2019-08-30
EP3490992B1 (en) 2023-03-22
CL2019000248A1 (es) 2019-06-21
WO2018026779A1 (en) 2018-02-08
SG10202101055VA (en) 2021-03-30
KR102465758B1 (ko) 2022-11-09
AU2021240150A1 (en) 2021-10-28
PH12019500202A1 (en) 2019-07-29
MX2019001319A (es) 2019-07-04
KR20190033595A (ko) 2019-03-29
CO2019000945A2 (es) 2019-02-08
CA3031537A1 (en) 2018-02-08
US20190177334A1 (en) 2019-06-13
JP2022120019A (ja) 2022-08-17
JP7448766B2 (ja) 2024-03-13
CN109937204B (zh) 2022-11-25
JP2019527233A (ja) 2019-09-26
US20230312591A1 (en) 2023-10-05
EP3490992A1 (en) 2019-06-05
IL264514B (en) 2021-09-30
US20220220119A1 (en) 2022-07-14
US11530223B2 (en) 2022-12-20
BR112019001768A2 (pt) 2019-06-11
US11299495B2 (en) 2022-04-12
SG11201900443VA (en) 2019-02-27
IL264514A (en) 2019-02-28

Similar Documents

Publication Publication Date Title
PE20190503A1 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos
PE20190501A1 (es) Moduladores nmda espiro-lactam y metodos de uso de los mismos
PE20190504A1 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos
PE20190502A1 (es) Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos
PE20190500A1 (es) Moduladores del receptor nmda spiro-lactam y uso de los mismos
AR109561A1 (es) Compuestos modulares de receptores tipo toll
PE20191495A1 (es) Piridonamidas como moduladores de canales de sodio
MX2020006460A (es) Compuestos de anillo 5,5 fusionado sustituido con diarilo como inhibidores de c5ar.
PE20190437A1 (es) Procesos para la preparacion de (s)-n-(5-((r)-2-(2,5-difluorofenil)pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidin-1-carboxamida y sales del mismo
AR083849A1 (es) Antagonistas de mdm2 de espiro-oxindol
CR20170250A (es) TETRAHIDRO-PIRIDO[3,4-b]INDOLES MODULADORES DE RECEPTORES DE ESTRÓGENOS Y USOS DE LOS MISMOS
PE20151427A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos
AR054035A1 (es) Derivados benzodioxano y benzodioxolano y uso de los mismos
AR076460A1 (es) Antagonistas del receptor cxcr3
AR094735A1 (es) Benzamidas sustituidas con actividad hacia receptores ep4
PE20211455A1 (es) Moduladores del receptor nmda espiro-lactama y usos de los mismos
EA201692542A1 (ru) Индановые и индолиновые производные и их применение в качестве активаторов растворимой гуанилатциклазы
PH12019502562A1 (en) N-substituted indole derivatives
BR112018005589A2 (pt) “composto, composição farmaceuticamente aceitável, e, uso de um composto”
MX2020011405A (es) Derivados de bencimidazol como moduladores del receptor gamma huerfano (rory) relacionado con retinoide y usos farmaceuticos de los mismos.
ECSP19062381A (es) Moduladores del receptor de estrógeno
CL2020001140A1 (es) Compuestos espirocíclicos como moduladores del receptor farnesoide x.
EA202092829A1 (ru) Композиции тофацитиниба с контролируемым высвобождением
EA201990765A1 (ru) Азаиндазольные соединения для применения при повреждениях сухожилий и/или связок
CU24434B1 (es) Compuestos derivados de n-(1,5-dimetil-3-oxo-2,3-dihidro-1h-pirazol-4-il)-4-metil-5-isoxazol-3-carboxamida activos como inhibidores selectivos de smurf-1